Randomised, Multicenter Phase III Clinical Study Of Nanoplatin Plus Pemetrexed Versus Cisplatin Plus Pemetrexed As First Line Treatment In Inoperable (Stage III/IV) Non-Small Cell Lung Cancer Of Non-Squamous Type
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2016
At a glance
- Drugs Cisplatin (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Regulon
- 05 Oct 2016 Status changed from planning to recruiting.
- 12 Jun 2012 Planned number of patients changed to 880, according to a Regulon media release.
- 12 Jun 2012 New trial record